Clopidogrel Tablet, Film Coated
Product Images NDC 71335-0080

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71335-0080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This is a figure showing the exposure to Clopidogrel Active Metabolite after taking multiple doses of Clopidogrel Bisulfate alone or with Proton Pump Inhibitors (PPIs). The effect of co-administered PPIs on the active metabolite AUC is shown in mean and 90% confidence interval. The specific PPIs are listed and their corresponding change relative to clopidogrel bisulfate administered alone is plotted on the x-axis. No other information is available.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This appears to be a table showing the cumulative event rate percentage for different treatments (Plagebo + Aspirin and Clopidogrel Bisulfate + Aspirin) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It also includes a statistic showing statistical significance (P = 0.00009).*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This text appears to be a chart or table showing the number of deaths before the first discharge, with statistics for a placebo group and a group taking the drug clopidogrel. It includes percentages and a proportional risk reduction of 7%, with a p-value of 0.03. The chart also includes a timeline of days since randomization up to 28 days.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This is a medical study comparing the effects of Placebo and Clopidogrel. It reports the number of events and the percentage of patients with events in each group. There is also a graph showing the number of days since randomization and events related to death, re-infarction, and stroke.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This appears to be a graph that shows the cumulative event rate (in percentage) of fatal or non-fatal vascular events for Aspirin and Clopidogrel Bisultate over a period of 36 months of follow-up. There are time increments divided into months, from 0 to 36, and the vertical axis measures the cumulative event rate.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

This text seems to be a table or graph showing the number of patients with stroke, MI, and PAD under Qualifying Condition and their treatment with Clopidogrel Bisulfate and Aspirin. It also shows the percentage of patients who were given Clopidogrel Bisulfate and Aspirin, as well as the hazard ratio. The graph shows how Clopidogrel Bisulfate and Aspirin fare against each other in terms of efficacy in patients with the mentioned conditions.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

FDA Label Image

Label Image (Lbl713350080)

This is a medication description for Clopidogrel, a pink round tablet of 75mg used to prevent blood clots. It is produced by Aurobindo Pharma Limited and is equivalent to Plavix. It should be stored at a temperature of 20°-25°C (68°-77°F) and comes in a package of 90 tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.